MedTrace Logo

Daptomycin Versus Placebo in Patients With Neutropenia and Fever

NCT01216241 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2014-04-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the benefits and side effects of daptomycin compared to placebo for the treatment of neutropenic fever.

Conditions

Interventions

DRUG

Daptomycin

8 MG/KG IV

OTHER

Saline Placebo

50 ml normal saline once daily

DRUG

Daptomycin

8 mg/kg once daily

Sponsors & Collaborators

  • Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    collaborator INDUSTRY

  • University of Rochester

    lead OTHER

Principal Investigators

  • Robert F Betts, MD · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01216241 on ClinicalTrials.gov